Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ZBH 
Zimmer Biomet Holdings Inc (ZBH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: ZBH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -32.18% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 22.02B USD | Price to earnings Ratio 24.98 | 1Y Target Price 122.04 |
Price to earnings Ratio 24.98 | 1Y Target Price 122.04 | ||
Volume (30-day avg) 1881174 | Beta 1.04 | 52 Weeks Range 97.69 - 130.73 | Updated Date 03/27/2025 |
52 Weeks Range 97.69 - 130.73 | Updated Date 03/27/2025 | ||
Dividends yield (FY) 0.87% | Basic EPS (TTM) 4.43 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 11.77% | Operating Margin (TTM) 23.25% |
Management Effectiveness
Return on Assets (TTM) 4.65% | Return on Equity (TTM) 7.25% |
Valuation
Trailing PE 24.98 | Forward PE 13.46 | Enterprise Value 27703448464 | Price to Sales(TTM) 2.87 |
Enterprise Value 27703448464 | Price to Sales(TTM) 2.87 | ||
Enterprise Value to Revenue 3.61 | Enterprise Value to EBITDA 12.31 | Shares Outstanding 199063008 | Shares Floating 198475928 |
Shares Outstanding 199063008 | Shares Floating 198475928 | ||
Percent Insiders 0.2 | Percent Institutions 93.64 |
Analyst Ratings
Rating 3.47 | Target Price 124.5 | Buy 5 | Strong Buy 6 |
Buy 5 | Strong Buy 6 | ||
Hold 17 | Sell 1 | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
Zimmer Biomet Holdings Inc
Company Overview
History and Background
Zimmer Biomet Holdings Inc. was formed in 2015 through the merger of Zimmer and Biomet. Zimmer was founded in 1927, focusing on orthopedic products. Biomet was founded in 1977 and also specialized in orthopedics. The merger created a leading global musculoskeletal healthcare company.
Core Business Areas
- Americas: Develops, manufactures and markets orthopaedic reconstructive products; sports medicine, biologics, trauma, extremities and minimally invasive technology products; spine products; and bone cement. It operates in the United States, Canada and Latin America.
- Europe, Middle East and Africa (EMEA): Similar to Americas, offers a portfolio of products including orthopaedic reconstructive products; sports medicine, biologics, trauma, extremities and minimally invasive technology products; spine products; and bone cement.
- Asia Pacific: Similar to Americas, Provides a comprehensive portfolio including orthopaedic reconstructive products; sports medicine, biologics, trauma, extremities and minimally invasive technology products; spine products; and bone cement.
Leadership and Structure
The CEO is Ivan Tornos. The company operates with a global organizational structure, divided into geographic regions and product-based divisions. It reports to a board of directors.
Top Products and Market Share
Key Offerings
- Knee Implants: Zimmer Biomet offers a wide range of knee implants for total and partial knee replacement. Zimmer Biomet market share in knee reconstruction is estimated to be around 30%. Competitors include Stryker, DePuy Synthes (Johnson & Johnson), and Smith & Nephew.
- Hip Implants: Zimmer Biomet's hip implants include solutions for primary and revision hip arthroplasty. Zimmer Biomet market share in hip reconstruction is estimated to be around 25%. Competitors include Stryker, DePuy Synthes (Johnson & Johnson), and Smith & Nephew.
- S.E.T. (Sports Medicine, Extremities, Trauma): This segment focuses on products used in sports medicine procedures, extremity repair, and trauma surgery. Market share data is more fragmented in this segment, but Zimmer Biomet is a significant player. Major competitors include Arthrex, Smith & Nephew and Stryker.
- Spine: This segment focuses on products used for procedures on the spine, including implants, biologics and minimally invasive technologies. Market share data is more fragmented in this segment, but Zimmer Biomet is a significant player. Major competitors include Medtronic, Johnson & Johnson (DePuy Synthes) and Nuvasive.
Market Dynamics
Industry Overview
The musculoskeletal healthcare industry is driven by an aging population, increasing prevalence of chronic conditions like osteoarthritis, and advancements in surgical techniques and implant technologies. It's a highly regulated industry with significant R&D investments.
Positioning
Zimmer Biomet is a leading player in the orthopedic market. It competes on product innovation, global reach, and a comprehensive portfolio of solutions. Competitive advantages include a strong brand reputation and extensive distribution network.
Total Addressable Market (TAM)
The global orthopedic devices market is expected to reach approximately $60 billion by 2028. Zimmer Biomet is positioned to capture a significant share of this TAM through its diverse product offerings and global presence.
Upturn SWOT Analysis
Strengths
- Global brand recognition
- Comprehensive product portfolio
- Extensive distribution network
- Strong R&D capabilities
- Established relationships with surgeons and hospitals
Weaknesses
- Integration challenges from the Zimmer-Biomet merger
- Exposure to pricing pressures and reimbursement changes
- Product liability risks
- High debt levels
- Slower growth in certain product categories compared to competitors
Opportunities
- Expanding into emerging markets
- Developing new and innovative products
- Leveraging digital technologies and data analytics
- Acquiring complementary businesses
- Capitalizing on the growing demand for minimally invasive procedures
Threats
- Increased competition from existing and new players
- Technological disruptions
- Adverse regulatory changes
- Economic downturns
- Cybersecurity risks
Competitors and Market Share
Key Competitors
- JNJ
- SYK
- BSX
- MDTC
Competitive Landscape
Zimmer Biomet is a market leader, but faces intense competition. Its advantages lie in its product breadth and global reach. Disadvantages include integration complexities and exposure to pricing pressures.
Major Acquisitions
Relievant Medsystems
- Year: 2023
- Acquisition Price (USD millions): 85
- Strategic Rationale: Expand into the growing market for non-surgical treatment of chronic low back pain.
Growth Trajectory and Initiatives
Historical Growth: Growth has been steady, but has had it's challenges due to it's global footprint.
Future Projections: Future projections depend on product innovation, market expansion, and successful execution of strategic initiatives. Analyst estimates project moderate revenue growth in the coming years.
Recent Initiatives: Focus on digital solutions, robotic surgery, and personalized medicine are examples of current initiatives.
Summary
Zimmer Biomet is a major player in the orthopedics market with a broad product portfolio and a global presence. Its strengths include its brand recognition and established distribution network. However, the company faces challenges related to integration and pricing pressures. Future success depends on innovation, market expansion, and successful execution of strategic initiatives in the robotics field.
Similar Companies
- JNJ
- SYK
- BSX
- MDTC
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Industry Reports (e.g., EvaluateMedTech)
- Analyst Reports (e.g., from major investment banks)
- Company Website
- Investor Presentations
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market data is dynamic and subject to change. Conduct thorough research before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zimmer Biomet Holdings Inc
Exchange NYSE | Headquaters Warsaw, IN, United States | ||
IPO Launch date 2001-07-25 | President, CEO & Director Mr. Ivan Tornos | ||
Sector Healthcare | Industry Medical Devices | Full time employees 17000 | Website https://www.zimmerbiomet.com |
Full time employees 17000 | Website https://www.zimmerbiomet.com | ||
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.